PharmTech News

Articles

Under a collaboration potentially worth more than $1.5 billion, the companies aim to develop the antisense therapy to treat patients with certain cardiovascular and metabolic diseases.

Pfizer, Akcea Partner for New Antisense Therapy in Deal Potentially Worth $1.5 Billion

The new joint venture, named Oerth Bio, will use Arvinas’ Protac technology to develop innovative new agricultural products. As part of its collaboration with Arvinas, Bayer is also using this technology to develop human therapeutics.

Bayer, Arvinas Launch Joint Venture for Targeted Protein Degradation Products

Agnes Shanley is senior editor of Pharmaceutical Technology.

The root cause of NDMA contamination may go well beyond manufacturing problems, to the molecule itself.

Problems With Ranitidine May Transcend Manufacturing Issues

The $243 million will be paid upon completion of the agreements along with sales-contingent milestones of up to $33 million in 2021 and 2022.

AstraZeneca Announces Sale of Acid Reduction Drug for $243 Million

GSK’s expanded R&D and manufacturing facility in Upper Merion, PA houses a new analytical lab and flexible manufacturing equipment, including single-use bioreactors.

GSK Invests $120 million in US Biopharmaceutical Manufacturing Facility

The new CMO combines SK Biotek in Korea, SK Biotek in Ireland, and AMPAC Fine Chemicals in the US to form SK Pharmteco.

AMPAC Fine Chemicals Merged into New SK Holdings CMO

Colorcon Ventures looks to fund promising startups in drug manufacturing, delivery, and supply chain.

Colorcon Launches $50 Million Venture Capital Fund

The acquisition will enhance Lundbeck’s brain disease therapy portfolio as well as its antibody process and development capabilities.

Lundbeck to Acquire Alder BioPharmaceuticals in Deal Worth Up to $1.95 Billion

EMA plans to issue new guidance, as US and European regulators respond to reports of nitrosamine contamination in H2 blockers, including Zantac, that contain rantidine.


Regulators Tackle Nitrosamine Contamination in Prescription and OTC Ulcer and Heartburn Medications

States oppose the company’s plans for a Chapter 11 settlement, which would restructure the company as a trust and cap funding to plaintiffs, Reuters and other news outlets report.

Top News